治疗性抗体体外作用模式可能的错误解读：同型黏附和流式细胞术导致人为的直接细胞死亡。 - Suppr

Suppr

超能文献

Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death.

作者信息

Golay Josée, Bologna Luca, André Pierre-Alain, Buchegger Franz, Mach Jean Pierre, Boumsell Laurence, Introna Martino

出版信息

Blood. 2010 Oct 28;116(17):3372-3; author reply 3373-4. doi: 10.1182/blood-2010-06-289736.

DOI:10.1182/blood-2010-06-289736

PMID:21030571

Abstract

摘要

相似文献

Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death.治疗性抗体体外作用模式可能的错误解读：同型黏附和流式细胞术导致人为的直接细胞死亡。

Blood. 2010 Oct 28;116(17):3372-3; author reply 3373-4. doi: 10.1182/blood-2010-06-289736.

GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.GA-101，一种用于治疗B细胞淋巴瘤的第三代人源化糖基工程抗CD20单克隆抗体。

Curr Opin Investig Drugs. 2009 Jun;10(6):588-96.

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells.针对CD20和HLA - DR的单克隆抗体可引发人淋巴瘤和白血病细胞的同型黏附，随后通过溶酶体介导细胞死亡。

J Clin Invest. 2009 Aug;119(8):2143-59. doi: 10.1172/JCI37884. Epub 2009 Jul 20.

Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.抗HLA - DR和CD20单克隆抗体（Lym - 1和利妥昔单抗）对人淋巴瘤细胞的抗淋巴瘤作用。

Cancer Biother Radiopharm. 2004 Oct;19(5):545-61. doi: 10.1089/cbr.2004.19.545.

The in vitro biological activity of the HLA-DR-binding clinical IgG4 antibody 1D09C3 is a consequence of the disruption of cell aggregates and can be abrogated by Fab arm exchange.HLA-DR结合临床IgG4抗体1D09C3的体外生物学活性是细胞聚集体破坏的结果，并且可以通过Fab臂交换消除。

Mol Immunol. 2009 Oct;46(16):3269-77. doi: 10.1016/j.molimm.2009.07.031. Epub 2009 Aug 21.

New monoclonal antibody approved as lymphoma therapy.新型单克隆抗体获批用于淋巴瘤治疗。

Am J Health Syst Pharm. 1998 Jan 15;55(2):110. doi: 10.1093/ajhp/55.2.110b.

Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101.抗组织蛋白酶B抗体的意外交叉反应导致了关于抗CD20单克隆抗体GA101作用机制的不确定性。

Leuk Res. 2017 Apr;55:41-48. doi: 10.1016/j.leukres.2017.01.010. Epub 2017 Jan 18.

AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients.抗CD20单克隆抗体：改善淋巴瘤患者的治疗策略及疗效

Expert Rev Anticancer Ther. 2002 Jun;2(3):323-9. doi: 10.1586/14737140.2.3.323.

[Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].利妥昔单抗治疗CD20+B细胞非霍奇金淋巴瘤的临床观察

Zhonghua Er Ke Za Zhi. 2003 Aug;41(8):627.

[First monoclonal antibody accepted for cancer therapy].[首个被批准用于癌症治疗的单克隆抗体]

Duodecim. 1998;114(6):509, 511.

引用本文的文献

Direct Cell Death Induced by CD20 Monoclonal Antibodies on B Cell Lymphoma Cells Revealed by New Protocols of Analysis.新分析方案揭示CD20单克隆抗体对B细胞淋巴瘤细胞的直接细胞死亡作用

Cancers (Basel). 2023 Feb 9;15(4):1109. doi: 10.3390/cancers15041109.

Role of Calcium Signaling in GA101-Induced Cell Death in Malignant Human B Cells.钙信号在GA101诱导的人恶性B细胞死亡中的作用

Cancers (Basel). 2019 Mar 1;11(3):291. doi: 10.3390/cancers11030291.

A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.新型II型抗CD20单克隆抗体奥滨尤妥珠单抗（GA101）治疗B细胞恶性肿瘤患者的综述

Adv Ther. 2017 Feb;34(2):324-356. doi: 10.1007/s12325-016-0451-1. Epub 2016 Dec 21.

Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope.预测毒理学方法在单克隆抗体治疗药物中的适用性：现状与范围。

Arch Toxicol. 2017 Apr;91(4):1595-1612. doi: 10.1007/s00204-016-1876-7. Epub 2016 Oct 20.

Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization.通过启动CD20-TNFR1共定位诱导神经酰胺/溶酶体参与的细胞死亡来对抗利妥昔单抗耐药性。

Oncoimmunology. 2016 Feb 18;5(5):e1143995. doi: 10.1080/2162402X.2016.1143995. eCollection 2016 May.

Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.用新型多组分抗CD20单克隆抗体纳米簇抑制利妥昔单抗耐药的B细胞淋巴瘤

Oncotarget. 2015 Sep 15;6(27):24192-204. doi: 10.18632/oncotarget.4206.

Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?利妥昔单抗治疗儿童和青少年后的免疫重建和感染并发症：我们从成人那里了解到什么，又可以学到什么？

Cancers (Basel). 2015 Jan 29;7(1):305-28. doi: 10.3390/cancers7010305.

Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics.利妥昔单抗的药代动力学和药效学为临床带来的启示。

MAbs. 2013 Nov-Dec;5(6):826-37. doi: 10.4161/mabs.26008. Epub 2013 Aug 8.

Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model.奥滨尤妥珠单抗和利妥昔单抗在滤泡性淋巴瘤 3D 模型中的抗肿瘤活性。

Blood Cancer J. 2013 Aug 9;3(8):e131. doi: 10.1038/bcj.2013.32.

Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells.膜微域鞘脂对于抗 CD20 诱导的慢性淋巴细胞白血病 B 细胞死亡是必需的。

Haematologica. 2012 Feb;97(2):288-96. doi: 10.3324/haematol.2011.051938. Epub 2011 Nov 4.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验